Biotechnology Acquisitions in Tennessee

Crown Laboratories, a Hildred Capital portfolio company, completed the acquisition of Revance Therapeutics through a cash tender offer that expired February 4, 2025; the transaction closed on February 6, 2025 and Revance will be delisted from Nasdaq. The deal brings together Crown's skincare and consumer brands with Revance's DAXXIFY, RHA dermal fillers and other aesthetics/therapeutic offerings to expand product portfolio and commercialization capabilities across medical, retail and e-commerce channels.

Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.

Charles River Laboratories agreed to acquire Cognate BioServices for approximately $875 million in cash, expanding Charles River's capabilities into the high-growth cell and gene therapy CDMO sector. Cognate, headquartered in Memphis, Tennessee with over 500 employees, will provide Charles River integrated cell and gene therapy development, testing, and CGMP manufacturing capabilities; the deal was expected to close by end of Q1 2021.